CY1124091T1 - Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας - Google Patents
Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτηταςInfo
- Publication number
- CY1124091T1 CY1124091T1 CY20211100387T CY211100387T CY1124091T1 CY 1124091 T1 CY1124091 T1 CY 1124091T1 CY 20211100387 T CY20211100387 T CY 20211100387T CY 211100387 T CY211100387 T CY 211100387T CY 1124091 T1 CY1124091 T1 CY 1124091T1
- Authority
- CY
- Cyprus
- Prior art keywords
- polypeptide molecule
- dual specificity
- improved dual
- specificity polypeptide
- binding domain
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 230000009977 dual effect Effects 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 230000027455 binding Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με ένα διειδικό πολυπεπτιδικό μόριο που αποτελείται από μια πρώτη πολυπεπτιδική αλυσίδα και μια δεύτερη πολυπεπτιδική αλυσίδα που παρέχει μια περιοχή πρόσδεσης προερχόμενη από έναν υποδοχέα Τ-κυττάρων (TCR) που είναι ειδική για έναν επίτοπο του ιικού πεπτιδίου σχετιζόμενο με μείζον σύμπλεγμα ιστοσυμβατότητας (MHC) και μια περιοχή πρόσδεσης προερχόμενη από ένα αντίσωμα ικανό να στρατολογεί ανθρώπινα ανοσοδραστικά κύτταρα μέσω ειδικής πρόσδεσης σε ένα επιφανειακό αντιγόνο των εν λόγω κυττάρων, καθώς και μεθόδους παρασκευής του διειδικού πολυπεπτιδικού μορίου και των χρήσεων του.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532713P | 2017-07-14 | 2017-07-14 | |
| DE102017115966.5A DE102017115966A1 (de) | 2017-07-14 | 2017-07-14 | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| DE102017119866 | 2017-08-30 | ||
| US201862658318P | 2018-04-16 | 2018-04-16 | |
| DE102018108995 | 2018-04-16 | ||
| PCT/EP2018/069157 WO2019012141A1 (en) | 2017-07-14 | 2018-07-13 | IMPROVED POLYPEPTIDE MOLECULE WITH DOUBLE SPECIFICITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124091T1 true CY1124091T1 (el) | 2022-05-27 |
Family
ID=62951983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100387T CY1124091T1 (el) | 2017-07-14 | 2021-05-06 | Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας |
| CY20211100934T CY1124835T1 (el) | 2017-07-14 | 2021-11-01 | Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100934T CY1124835T1 (el) | 2017-07-14 | 2021-11-01 | Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US20190016802A1 (el) |
| EP (3) | EP3428194B1 (el) |
| JP (4) | JP2020530762A (el) |
| KR (2) | KR20200026994A (el) |
| CN (2) | CN110914308A (el) |
| AU (2) | AU2018298884A1 (el) |
| BR (2) | BR112020000769A2 (el) |
| CA (2) | CA3069842A1 (el) |
| CO (2) | CO2020001029A2 (el) |
| CR (2) | CR20200014A (el) |
| CY (2) | CY1124091T1 (el) |
| DK (2) | DK3652215T3 (el) |
| ES (2) | ES2871146T3 (el) |
| HR (1) | HRP20211744T1 (el) |
| HU (2) | HUE054568T2 (el) |
| LT (2) | LT3652215T (el) |
| MA (1) | MA46299B1 (el) |
| MD (2) | MD3652215T2 (el) |
| MX (1) | MX2020011744A (el) |
| PE (2) | PE20200614A1 (el) |
| PL (2) | PL3428194T3 (el) |
| PT (2) | PT3428194T (el) |
| RS (2) | RS61817B1 (el) |
| SG (2) | SG11202000027WA (el) |
| SI (2) | SI3428194T1 (el) |
| TW (2) | TWI817302B (el) |
| WO (2) | WO2019012138A1 (el) |
| ZA (1) | ZA202000842B (el) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200614A1 (es) * | 2017-07-14 | 2020-03-11 | Immatics Biotechnologies Gmbh | Molecula de polipeptido con especificidad dual mejorada |
| EP3794035A1 (en) | 2018-05-14 | 2021-03-24 | Immunocore Limited | Bifunctional binding polypeptides |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| EA202193139A1 (ru) | 2019-05-27 | 2022-03-01 | Имматикс Юс, Инк. | Вирусные векторы и их применение в адоптивной клеточной терапии |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| WO2021113748A1 (en) * | 2019-12-05 | 2021-06-10 | Arbele Corp. | Composition of triaxial antibodies and method of making and using thereof |
| BR112022016909A2 (pt) | 2020-02-24 | 2022-12-06 | Immatics Us Inc | Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| KR20230135589A (ko) | 2020-12-31 | 2023-09-25 | 이매틱스 유에스 인코포레이티드 | Cd8 폴리펩타이드, 조성물 및 이의 사용 방법 |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| CA3217738A1 (en) | 2021-05-05 | 2022-05-04 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230190806A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of treating metastatic lesions and compositions thereof |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4448570A1 (en) * | 2021-12-14 | 2024-10-23 | CDR-Life AG | Dual mhc-targeting t cell engager |
| KR20240149435A (ko) | 2022-02-20 | 2024-10-14 | 이뮤노코어 리미티드 | Hiv 특이적 결합 분자 |
| WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023209124A1 (en) | 2022-04-29 | 2023-11-02 | Immatics Biotechnologies Gmbh | Mammalian display platform for multispecific antigen binding proteins |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2024033332A1 (en) | 2022-08-08 | 2024-02-15 | Immatics Biotechnologies Gmbh | Guided positional scanning method |
| WO2024130179A1 (en) | 2022-12-16 | 2024-06-20 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| WO2024146951A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a prame peptide-hla complex |
| WO2024146936A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a piwil1 peptide-hla complex |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| EP0744958B1 (en) | 1994-01-31 | 2003-06-25 | Trustees Of Boston University | Polyclonal antibody libraries |
| WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| AU2002330162B2 (en) | 2001-10-01 | 2008-08-07 | Takeda Pharmaceutical Company Limited | Multi-chain eukaryotic display vectors and uses thereof |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| EP1863842A2 (en) | 2005-04-01 | 2007-12-12 | MediGene Ltd. | High affinity hiv t cell receptors |
| EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US10000757B2 (en) | 2005-05-27 | 2018-06-19 | Ospedale San Raffaele S.R.L. | Gene vector |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| JP2011525103A (ja) | 2008-01-11 | 2011-09-15 | モルフォシス・アー・ゲー | ディスプレイベクター並びにその方法及び用途 |
| EP2258719A1 (en) * | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| EA201492253A1 (ru) | 2009-12-29 | 2015-06-30 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | Конструкторы, связывающиеся с ron, и способы их использования |
| US20120294857A1 (en) | 2010-01-11 | 2012-11-22 | Trustees Of Dartmouth College | Monomeric Bi-Specific Fusion Protein |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| AR084053A1 (es) | 2010-11-30 | 2013-04-17 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad |
| SG10201602159VA (en) | 2011-02-11 | 2016-04-28 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| WO2013026837A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| BR112015011111A2 (pt) | 2012-11-30 | 2017-11-14 | Roche Glycart Ag | proteína multifuncional e formulação farmacêutica |
| CA2891493C (en) * | 2013-02-26 | 2022-03-15 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| JP2016512421A (ja) | 2013-02-26 | 2016-04-28 | ロシュ グリクアート アーゲー | 二重特異性ｔ細胞活性化抗原結合分子 |
| RU2721707C2 (ru) | 2013-03-14 | 2020-05-21 | Макродженикс, Инк. | Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор |
| CN105980409B (zh) | 2013-11-27 | 2023-07-18 | 酵活生物制药有限公司 | 靶向her2的双特异性抗原结合构建体 |
| TWI701261B (zh) | 2013-12-17 | 2020-08-11 | 美商建南德克公司 | 抗cd3抗體及使用方法 |
| CA2943786C (en) | 2014-03-25 | 2023-12-12 | Merial, Inc. | Immunological compositions containing attenuated histophilus somni |
| CN106795217B (zh) | 2014-07-24 | 2021-08-06 | 蓝鸟生物公司 | Bcma嵌合抗原受体 |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| EA201791121A1 (ru) * | 2014-11-20 | 2018-04-30 | Ф. Хоффманн-Ля Рош Аг | Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3 |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| WO2016154585A1 (en) | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| EP3095792A1 (en) * | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| MY189596A (en) | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| US10130693B2 (en) | 2015-08-28 | 2018-11-20 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017059900A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| MA45004A (fr) | 2015-10-09 | 2019-03-27 | Immatics Biotechnologies Gmbh | Anticorps spécifiques anti-wt1-hla |
| RU2767209C2 (ru) * | 2015-10-23 | 2022-03-16 | Еурека Терапьютикс, Инк. | Химерные конструкции антитело/т-клеточный рецептор и их применения |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US11034767B2 (en) | 2016-04-15 | 2021-06-15 | Trustees Of Dartmouth College | High affinity B7-H6 antibodies and antibody fragments |
| KR102436129B1 (ko) | 2016-06-17 | 2022-08-26 | 메디진 이뮤노테라피스 게엠바하 | T 세포 수용체 및 이의 용도 |
| MX2018015937A (es) | 2016-06-27 | 2019-05-02 | Procter & Gamble | Aparato y metodo para evaluar un tratamiento para la sensibilidad dental mediante producto para el cuidado bucal. |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| WO2018026018A1 (ja) | 2016-08-05 | 2018-02-08 | 国立大学法人東北大学 | Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 |
| WO2018050902A2 (en) | 2016-09-15 | 2018-03-22 | Quadrucept Bio Limited | Multimers, tetramers & octamers |
| CN106831996B (zh) | 2017-03-31 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 |
| WO2018220216A1 (en) | 2017-06-01 | 2018-12-06 | Universität Stuttgart | Heterodimerizing ig domains |
| PE20200614A1 (es) * | 2017-07-14 | 2020-03-11 | Immatics Biotechnologies Gmbh | Molecula de polipeptido con especificidad dual mejorada |
| WO2019047932A1 (zh) | 2017-09-08 | 2019-03-14 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| JPWO2019151392A1 (ja) | 2018-01-31 | 2021-02-04 | 国立大学法人東北大学 | 抗原特異的ｍｈｃ発現調節法 |
| EP3794035A1 (en) | 2018-05-14 | 2021-03-24 | Immunocore Limited | Bifunctional binding polypeptides |
| EA202091977A1 (ru) | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| US20220275043A1 (en) | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| WO2020057610A1 (en) | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| KR20220075210A (ko) | 2019-07-15 | 2022-06-07 | 네오진 테라퓨틱스 비.브이. | Tcr 유전자를 단리하기 위한 방법 |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CN114502578A (zh) | 2019-09-06 | 2022-05-13 | 伊莱利利公司 | 包含t-细胞受体恒定结构域的蛋白 |
| EP4034245A1 (en) | 2019-09-25 | 2022-08-03 | Universität Stuttgart | Trivalent binding molecules |
| JP2022549351A (ja) | 2019-09-27 | 2022-11-24 | アジェナス インコーポレイテッド | ヘテロ二量体タンパク質 |
| KR20220098379A (ko) | 2019-11-15 | 2022-07-12 | 그릿스톤 바이오, 인코포레이티드 | 공유 네오항원을 표적으로 하는 항원-결합 단백질 |
| CN115103852A (zh) | 2019-11-18 | 2022-09-23 | 德国生物新技术公司 | Prame tcr受体和其用途 |
| JP2023507729A (ja) | 2019-12-17 | 2023-02-27 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 腫瘍抗原を標的とするｍａｎａボディおよび使用方法 |
| CN110964122B (zh) | 2019-12-24 | 2022-04-15 | 南京北恒生物科技有限公司 | T细胞受体融合蛋白及其用途 |
| CA3171906A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| US20230130925A1 (en) | 2020-03-16 | 2023-04-27 | University Of Southern California | Methods to prevent, ameliorate and treat complications from viral infections |
| WO2021222576A1 (en) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
| AU2021289612A1 (en) | 2020-06-10 | 2023-01-19 | The University Of Melbourne | HIV-1 antibodies |
| EP4188416A4 (en) | 2020-07-27 | 2024-08-21 | Univ Arizona | MULTIFUNCTIONAL IMMUNOGLOBULIN FOLDING POLYPEPTIDES FROM ALTERNATIVE TRANSLATION INITIATION AND TERMINATION |
| WO2022076788A1 (en) | 2020-10-09 | 2022-04-14 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
| WO2022083668A1 (en) | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Use of a chimeric co-stimulatory receptor for cell therapy |
| KR20230123474A (ko) | 2020-12-21 | 2023-08-23 | 자임워크스 비씨 인코포레이티드 | 안정화된 tcr 작제물 및 사용 방법 |
| CA3208717A1 (en) | 2021-02-19 | 2022-08-25 | Preet M. Chaudhary | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
-
2018
- 2018-07-13 PE PE2020000056A patent/PE20200614A1/es unknown
- 2018-07-13 WO PCT/EP2018/069151 patent/WO2019012138A1/en active Application Filing
- 2018-07-13 EP EP18183508.3A patent/EP3428194B1/en active Active
- 2018-07-13 US US16/035,412 patent/US20190016802A1/en not_active Abandoned
- 2018-07-13 PL PL18183508T patent/PL3428194T3/pl unknown
- 2018-07-13 JP JP2020501174A patent/JP2020530762A/ja active Pending
- 2018-07-13 EP EP21191794.3A patent/EP3985029A1/en active Pending
- 2018-07-13 MA MA46299A patent/MA46299B1/fr unknown
- 2018-07-13 CN CN201880046726.5A patent/CN110914308A/zh active Pending
- 2018-07-13 RS RS20210561A patent/RS61817B1/sr unknown
- 2018-07-13 ES ES18740829T patent/ES2871146T3/es active Active
- 2018-07-13 PL PL18740829T patent/PL3652215T3/pl unknown
- 2018-07-13 HU HUE18740829A patent/HUE054568T2/hu unknown
- 2018-07-13 CN CN201880046721.2A patent/CN110914307A/zh active Pending
- 2018-07-13 WO PCT/EP2018/069157 patent/WO2019012141A1/en active Application Filing
- 2018-07-13 AU AU2018298884A patent/AU2018298884A1/en active Pending
- 2018-07-13 KR KR1020207004219A patent/KR20200026994A/ko not_active Application Discontinuation
- 2018-07-13 US US16/035,420 patent/US20190016803A1/en not_active Abandoned
- 2018-07-13 HR HRP20211744TT patent/HRP20211744T1/hr unknown
- 2018-07-13 MD MDE20200533T patent/MD3652215T2/ro unknown
- 2018-07-13 AU AU2018298881A patent/AU2018298881A1/en active Pending
- 2018-07-13 LT LTEP18740829.9T patent/LT3652215T/lt unknown
- 2018-07-13 CR CR20200014A patent/CR20200014A/es unknown
- 2018-07-13 US US16/035,429 patent/US20190016804A1/en not_active Abandoned
- 2018-07-13 DK DK18740829.9T patent/DK3652215T3/da active
- 2018-07-13 LT LTEP18183508.3T patent/LT3428194T/lt unknown
- 2018-07-13 PT PT181835083T patent/PT3428194T/pt unknown
- 2018-07-13 HU HUE18183508A patent/HUE057110T2/hu unknown
- 2018-07-13 DK DK18183508.3T patent/DK3428194T3/da active
- 2018-07-13 KR KR1020207004221A patent/KR20200026995A/ko not_active Application Discontinuation
- 2018-07-13 MD MDE20190844T patent/MD3428194T2/ro unknown
- 2018-07-13 RS RS20211381A patent/RS62544B1/sr unknown
- 2018-07-13 US US16/035,403 patent/US11905328B2/en active Active
- 2018-07-13 SI SI201830456T patent/SI3428194T1/sl unknown
- 2018-07-13 CA CA3069842A patent/CA3069842A1/en active Pending
- 2018-07-13 SI SI201830285T patent/SI3652215T1/sl unknown
- 2018-07-13 CA CA3069610A patent/CA3069610A1/en active Pending
- 2018-07-13 PT PT187408299T patent/PT3652215T/pt unknown
- 2018-07-13 SG SG11202000027WA patent/SG11202000027WA/en unknown
- 2018-07-13 PE PE2020000058A patent/PE20200615A1/es unknown
- 2018-07-13 CR CR20200013A patent/CR20200013A/es unknown
- 2018-07-13 EP EP18740829.9A patent/EP3652215B1/en active Active
- 2018-07-13 BR BR112020000769-2A patent/BR112020000769A2/pt unknown
- 2018-07-13 ES ES18183508T patent/ES2898210T3/es active Active
- 2018-07-13 BR BR112020000762-5A patent/BR112020000762A2/pt unknown
- 2018-07-13 SG SG11202000025SA patent/SG11202000025SA/en unknown
- 2018-07-16 TW TW110149543A patent/TWI817302B/zh active
- 2018-07-16 TW TW107124492A patent/TWI762677B/zh active
- 2018-07-17 JP JP2018134424A patent/JP6784724B2/ja active Active
-
2020
- 2020-01-14 MX MX2020011744A patent/MX2020011744A/es unknown
- 2020-01-28 CO CONC2020/0001029A patent/CO2020001029A2/es unknown
- 2020-02-10 ZA ZA2020/00842A patent/ZA202000842B/en unknown
- 2020-02-11 CO CONC2020/0001491A patent/CO2020001491A2/es unknown
-
2021
- 2021-05-06 CY CY20211100387T patent/CY1124091T1/el unknown
- 2021-11-01 CY CY20211100934T patent/CY1124835T1/el unknown
-
2022
- 2022-03-03 US US17/686,358 patent/US20220185888A1/en not_active Abandoned
- 2022-03-12 US US17/693,323 patent/US20220195044A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023083663A patent/JP2023103451A/ja active Pending
- 2023-06-08 US US18/331,556 patent/US20230348598A1/en active Pending
- 2023-11-24 JP JP2023198791A patent/JP2024023385A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124091T1 (el) | Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας | |
| CY1121962T1 (el) | Υποδοχεις τ κυτταρου | |
| CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
| CY1124664T1 (el) | Υποδοχεις τ λεμφοκυτταρων | |
| CY1123783T1 (el) | Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| CY1124747T1 (el) | Ανθρωπινα αντισωματα σε pd-1 | |
| CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
| CY1122720T1 (el) | Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii | |
| AR106189A1 (es) | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO | |
| CL2023000896A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
| BR112018075653A2 (pt) | anticorpos anti-b7-h3 e conjugados anticorpo fármaco | |
| PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
| BR112018075649A2 (pt) | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| CY1120212T1 (el) | Πεπτιδια | |
| NZ756383A (en) | Antigen receptors and uses thereof | |
| EA202090250A1 (ru) | Усовершенствованная молекула полипептида с двойной специфичностью | |
| PH12020500095A1 (en) | Improved dual specific polypeptide molecule | |
| CY1120686T1 (el) | Αντισωματα ειδικα για το ανθρωπινο πολυπεπτιδιο αμυλοειδους των νησιδιων (ηιαρρ) και χρησεις αυτων | |
| EA202090580A2 (ru) | Триспецифичные связывающие молекулы и способы их применения |